First Blood-Based Lung Cancer EGFR Test Gets Green Light
This article was originally published in The Gray Sheet
Executive Summary
FDA has approved the first liquid biopsy test to detect genetic mutations linked to drug response in patients with non-small cell lung cancer. Roche's cobas EGFR Mutation Test v2 could be a game-changer in helping to diagnose certain NSCLC patients without requiring a tumor biopsy, the agency suggests.
You may also be interested in...
2016 Original PMAs And Panel-Track Supplements
A sortable and searchable table of FDA original PMAs and panel-track supplements approved in calendar year 2016, updated monthly. Latest update: approvals through June 30.
Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
The Gray Sheet spoke to Roche Molecular Diagnostic's top researcher, Walter Koch, about the promise of liquid biopsy soon after FDA approved its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
Diagnostics In 2015: Past Trends Coalesce, New Roads Open
The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.